Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 3

1.

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.

Hart WM, Abrams P, Munro V, Retsa P, Nazir J.

J Med Econ. 2013 Oct;16(10):1246-54. doi: 10.3111/13696998.2013.829079. Epub 2013 Sep 11.

PMID:
23885660
[PubMed - indexed for MEDLINE]
2.

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.

Wex J, Sidhu M, Odeyemi I, Abou-Setta AM, Retsa P, Tombal B.

Clinicoecon Outcomes Res. 2013 Jun 24;5:257-69. doi: 10.2147/CEOR.S44855. Print 2013.

PMID:
23836996
[PubMed]
Free PMC Article
3.

Deriving health state utilities for the numerical pain rating scale.

Dixon S, Poole CD, Odeyemi I, Retsa P, Chambers C, Currie CJ.

Health Qual Life Outcomes. 2011 Nov 3;9:96. doi: 10.1186/1477-7525-9-96.

PMID:
22054241
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk